Pfizer & BioNTech submits Phase 1 data to US FDA for booster dose Covid-19
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Lenalidomide is used to treat cancer and also some anaemia disorders
MTL, with over 40 years of experience in packaging, caters to the requirements of the FMCG, F&B, homecare, personal care, agrochemicals, pharmaceutical, and liquor industries
The group has a total of 320 ANDA approvals
The hospital chain aggressively embarks on digitisation and is e-health ready
The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)
This is the first of its kind vaccine for Covid 19 to get the go-ahead
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
The American Association for Clinical Chemistry (AACC); the American Society for Clinical Pathology (ASCP); the American Society of Hematology (ASH); and the International Myeloma Working Group (IMWG), collaborate to develop the guideline
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Subscribe To Our Newsletter & Stay Updated